Other Mutations: HER4

NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

NCT03297606
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, HER2, HER3, HER4, VEGFR, EGFR, FGFR, CDK, Akt, mTOR, PI3K, ALK, ROS, MET, KIT, PDGFR, POLE, POLD, RET, FLT, CSFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Any patient with an incurable metastatic solid tumor is eligible; The trial matches patients to a specific experimental arm based on mutations expressed by the tumor- see trial for full list of eligible mutations
Exclusions: Known active progressive brain metastases
https://ClinicalTrials.gov/show/NCT03297606

NCT03065387: Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation

NCT03065387
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR, HER2, HER3, HER4, KRAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must have EGFR, RAS, HER2, HER3, and/or HER4 somatic mutation or EGFR and/or HER2 gene amplification
Exclusions: Patients with known active central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03065387

Up ↑